Treatment strategies targeting IgE have been developed to manage allergic diseases. Omalizumab, a monoclonal antibody, is an example of a drug that binds to IgE and prevents it from interacting with its receptors on immune cells. This treatment is particularly effective for patients with severe allergic asthma. In toxicology, such therapies can be explored for managing hypersensitivity reactions to drugs and environmental toxins.
